Scientists raised $9 million today to fund clinical trials for a technology that illuminates cancer cells during surgery.
“What we are developing at GenapSys will enable the genomic revolution not only for healthcare, but for a wide range of applications,” said Dr. Hesaam Esfandyarpour, GenapSys founder and chief executive.
Guest Post Enterprise software is changing in many ways. It’s moving to the cloud. Profit margins are getting squeezed. Customers are cutting costs and demanding more. The onus is now on vendors to prove their value-add.
As you may have heard, Google is back in the health business with Calico, a new antiaging initiative. Now we know who is behind Calico — and just how much Google is betting on it.
Digital health accelerator Rock Health has selected its fifth class of startups. Given the burgeoning interest in the space, the team says this was its most competitive application process yet.
Today Fenwick & West released a study stating that the number of life science financings continued to decline in 2012, falling by more than $5 billion over the past five years.
The professional venture capital community is more diverse than ever, but employment is still largely dominated by white men, according to the results of a joint census conducted by the National Venture Capital Association and Dow Jones VentureSource, which was released today.
Fresh from the Department of Whistling Past the Graveyard in today’s VentureWire:
Life-science IPOs may be hitting the wall — so far this year, seven biotech and medical-device startups have yanked their offerings — but one part of the IPO market is booming. That’s the field of “special-purpose acquisition corporations,” or SPACs, which are essentially blank-check companies that raise money through initial offerings specifically for the purpose of acquiring other companies.
Last year was a tough one for IPOs, as Matt noted earlier, and so far this year looks even worse. Aptamer-drug maker Archemix today became the third life-science startup this month to withdraw or postpone an IPO, and the sixth so far this year. We take a closer look at the worsening IPO climate and the contrast with still-bullish venture funding in the sector, over at VentureBeat Life Sciences.